CARY, N.C. (January 17, 2018) Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, is now contracted with MedImpact Healthcare Systems, Inc. (“MedImpact”) to dispense specialty prescriptions under the MedImpact Direct Specialty program.

The MedImpact Direct Specialty program uses a specialty pharmacy hub between prescribers and the fulfillment pharmacy to serve as a plan sponsor and member advocate. The MedImpact Direct staff conducts plan-specific prescription-level utilization management before each drug is dispensed. MedImpact Direct Specialty provides plan information to the dispensing pharmacy that acts on that information with the prescriber to better align dispensing with plan formulary and utilization management rules.

“We are pleased to provide pharmacy services to members on behalf of the MedImpact Direct Specialty program,” said Paula Bickley, vice president, Market Access, McKesson Life Sciences. “Together, we are committed to creating a seamless, supportive experience for members of MedImpact’s clients to access and afford specialty oncology medication.”

Biologics receives member referrals directly from the MedImpact Direct Specialty program’s specialty hub. When a new referral is routed to Biologics, a member of the Biologics’ professional pharmacy staff reaches out to the member to coordinate prescription delivery and provide clinical consultation on oncology therapies.

“Biologics brings a depth of oncology expertise to the MedImpact Direct Specialty Pharmacy program,” said Greg Watanabe, president and chief operations officer of MedImpact Healthcare Systems. “Our innovative approach to managing specialty pharmacy benefits brings best-in-class dispensing partners to our clients and their plan participants.”

About MedImpact Direct Program®
MedImpact Direct, LLC manages a program on behalf of MedImpact that offers an easy-to-use benefit for maintenance and specialty drug therapies through a network of pharmacy partners. We serve as one source to control costs, utilization and the member experience. Prescription-level utilization management for all therapies, including limited distribution drugs, aligns dispensing with formulary, clinical guidelines and benefit design rules. Our model was created to be a consumer and plan sponsor advocate by providing more control and oversight between the physician/prescriber and pharmacy dispensing partners. MedImpact Direct, LLC is a wholly owned subsidiary of pharmacy benefit manager (PBM), MedImpact Healthcare Systems, Inc.

About MedImpact
MedImpact Healthcare Systems, Inc., an independent, trend-focused PBM™, is the nation’s largest privately held PBM, serving health plans, self-funded employers and government entities. Our business model is unique. We focus on effectively managing client pharmacy benefits to promote Lower Cost and Better Care through One Source. Our model aligns us with our clients. We help promote prescribing of lower-net-cost, medically appropriate drugs with fulfillment at the most appropriate participating pharmacy providing competitive pricing, good value and high-quality service. Our number-one goal is client satisfaction by providing flexible solutions and member-centric products with a focus on lowest-net cost and quality outcomes.


About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with over 24 years of experience connecting patients to life-changing medications in oncology and other complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics by McKesson delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As part of McKesson Life Sciences, a business within McKesson Corporation, Biologics by McKesson harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.

Media Contacts
Claire Crye, McKesson Life Sciences

Verona Macdonell, MedImpact and MedImpact Direct